Finch Therapeutics Group, Inc. (FNCH)
OTCMKTS
· Delayed Price · Currency is USD
10.80
-0.20 (-1.82%)
Dec 23, 2024, 4:00 PM EST
Finch Therapeutics Group Revenue
In the year 2023, Finch Therapeutics Group had annual revenue of $107.00K, down -87.57%.
Revenue
107.00K
Revenue Growth
-87.57%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
17.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 107.00K | -754.00K | -87.57% |
| Dec 31, 2022 | 861.00K | -17.67M | -95.35% |
| Dec 31, 2021 | 18.53M | 10.81M | 140.08% |
| Dec 31, 2020 | 7.72M | -2.44M | -23.98% |
| Dec 31, 2019 | 10.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.66B |
| Ryman Healthcare Limited | 458.44M |
| Verano Holdings Corp. | 897.57M |
| Vireo Growth Inc. | 98.53M |
| Medexus Pharmaceuticals Inc. | 104.76M |
Finch Therapeutics Group News
- 2 months ago - Finch Therapeutics looks to delist from the Nasdaq Global Select Market - Seeking Alpha
- 2 months ago - Finch Announces Delisting from Nasdaq and SEC Deregistration - GlobeNewsWire
- 1 year ago - Finch Announces Reverse Stock Split of Common Stock - GlobeNewsWire
- 1 year ago - Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 1 year ago - Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement - GlobeNewsWire
- 1 year ago - Finch Therapeutics: Why This Finch Could Fly - An Asymmetric Risk/Reward Opportunity - Seeking Alpha
- 1 year ago - Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 years ago - Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets - GlobeNewsWire